格隆汇8月25日丨赛伦生物(688163.SH)公布2025年半年度报告，报告期实现营业收入1.01亿元，同比增 长2.82%；归属于上市公司股东的净利润3297.67万元，同比增长2.07%；归属于上市公司股东的扣除非 经常性损益的净利润2852.71万元，同比增长25.08%；基本每股收益-0.30元。拟向全体股东每10股派发 现金红利1.20元（含税）。营业收入较上年同期增长2.82%，主要系本期抗蛇毒血清系列产品销量增长 推动营业收入同比微增。 ...

支付募投项目人员费用并以募集资金等额置换的核查意见 方正证券承销保荐有限责任公司 方正证券承销保荐有限责任公司(以下简称"保荐机构")作为上海赛伦生 物技术股份有限公司(以下简称"公司"或"赛伦生物")首次公开发行股票并 在科创板上市的保荐机构及持续督导机构,根据《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号一规范运作》《上 市公司募集资金监管规则》等法律法规及业务规则的规定,就赛伦生物使用自有 资金支付募投项目人员费用并以募集资金等额置换事项进行了核查,具体情况如 下: 关于上海赛伦生物技术股份有限公司使用自有资金 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准,公司获准向社 会公开发行人民币普通股 2,706 万股,每股面值为 1.00元,每股发行价格为 33.03 元,公司收到募集资金总额为 89,379.18 万元,扣除发行费用 10,886.82 万元,募 集资金净额为 78,492.36 万元。上述募集资金已于 2022年 3 月 4 日全部到位 ...

上海赛伦生物技术股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 为践行以"投资者为本"的上市公司发展理念，维护公司全体股东利益， 切实履行上市公司的责任和义务，上海赛伦生物技术股份有限公司（以下简称 "公司"）于 2025 年 4 月发布了 2025 年度"提质增效重回报"行动方案（以 下简称"行动方案"）。2025 年上半年，公司积极落实行动方案的相关举措。 为巩固成果、应对挑战、更好地推动高质量发展，公司认真评估了行动方案半 年度实施效果，于 2025 年 8 月 25 日召开了第四届董事会第八次会议审议通过 了《2025 年"提质增效重回报"行动方案的半年度评估报告》。现将行动方案 半年度实施情况报告如下： 一、聚焦经营主业，不断增强综合竞争力 公司继续深化产品学术推广，保持合理投入，持续推进精细化管理，确保 业务高效运行，整体经营业绩继续保持稳健增长；强化研发创新，完善研发版 图，不断加深和拓宽核心竞争力护城河。 2025 年上半年，公司实现营业收入 10,081.94 万元，较上年同期增长 2.82%； 实现归属于上市公司股东的净利润 3,297.67 万元，较上年同期 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-023 上海赛伦生物技术股份有限公司 关于自愿披露抗狂犬病血清挂网销售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）的抗狂犬病血清产品 近日已在部分省份的药品采购信息平台挂网，启动销售。 抗狂犬病血清具有特异性中和狂犬病毒的作用，用于对被疑似狂犬、狂犬或 者其他易感动物严重咬伤或多部位咬伤者进行预防注射。 剂型：注射剂 规格：每瓶 2.0ml，含狂犬病抗体不低于 400IU。 二、药品的其他相关情况 1、狂犬病免疫预防药物情况 抗狂犬病血清系公司已有产品，过去因流通渠道影响、过敏反应较大等原因， 未规模销售。公司对该产品持续进行工艺改进研究，于 2024 年下半年进行了生 产，2025 年持续推进在各个省份药品采购信息平台挂网工作，近日在部分省份 挂网。 为便于广大投资者了解该产品及市场情况，现将相关情况披露如下： 一、 药品基本情况 （3）本产品的应用场景 本产品在有犬伤处置资质的医疗机构的急诊或者动 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-022 上海赛伦生物技术股份有限公司 二、募集资金管理情况 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》及上海证券交易所发布的《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关规定，现将上海赛伦生物技 术股份有限公司（以下简称"公司"）2025 年半年度募集资金存放与实际使用 情况专项报告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获 准向社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价 格为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募集资金净额为 78,492.36 ...

关于使用自有资金支付募投项目人员费用 并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开第四届董事会第八次会议，审议通过了《关于使用自有资金支付募投项目人 员费用并以募集资金等额置换的议案》，同意公司在募投项目实施期间，根据实 际需要，先行使用自有资金支付募投项目人员费用，后续定期从募集资金专户划 转等额资金至公司自有资金账户进行置换，该部分等额置换资金视同募投项目使 用资金，上述事项无需提交公司股东会审议。保荐机构方正证券承销保荐有限责 任公司对本事项出具了明确的核查意见。现将具体情况公告如下： 一、募集资金基本情况 证券代码：688163 证券简称：赛伦生物 公告编号：2025-021 上海赛伦生物技术股份有限公司 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每 ...

[Part I Definitions](index=5&type=section&id=Part%20I%20Definitions) [Definitions of Common Terms](index=5&type=section&id=Definitions%20of%20Common%20Terms) This section defines key terms, company entities, and specialized biomedical terminology for clear report understanding - The report defines **'Company'** and **'Salubris Bio'** as Shanghai Salubris Bio-tech Co., Ltd., along with its wholly-owned subsidiary **'Salubris Dafeng'** and other entities[11](index=11&type=chunk) - Specialized biomedical terms, including antitoxin, antiserum, equine tetanus immunoglobulin, toxin, toxoid, serum, plasma, antivenom, anti-rabies serum, passive immunity, and active immunity, are explained to provide a foundation for understanding the company's business[11](index=11&type=chunk) [Part II Company Profile and Key Financial Indicators](index=6&type=section&id=Part%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) [I. Company Basic Information](index=6&type=section&id=I.%20Company%20Basic%20Information) This section provides Shanghai Salubris Bio-tech Co., Ltd.'s fundamental details, including name, legal representative, and addresses - The company's Chinese name is Shanghai Salubris Bio-tech Co., Ltd., abbreviated as **Salubris Bio**, with **Fan Zhihe** as its legal representative[13](index=13&type=chunk) - The company's registered and office address is at **1288 Huaqing Road, Qingpu District, Shanghai**, and its website is **www.serum-china.com.cn**[13](index=13&type=chunk) [II. Contact Persons and Information](index=6&type=section&id=II.%20Contact%20Persons%20and%20Information) This section provides contact details for the company's Board Secretary and Securities Affairs Representative - Board Secretary **Cheng Qiong** and Securities Affairs Representative **Xie Yuting** share the contact address at **1288 Huaqing Road, Qingpu District, Shanghai**, with phone and fax numbers **021-64959122**, and email **dmb@serum-china.com**[14](index=14&type=chunk) [III. Information Disclosure and Document Custody Location Changes](index=6&type=section&id=III.%20Information%20Disclosure%20and%20Document%20Custody%20Location%20Changes) This section outlines the company's designated newspapers and website for information disclosure - The company's designated newspapers for information disclosure are **"Shanghai Securities News"** and **"China Securities Journal"**[15](index=15&type=chunk) - The semi-annual report is published on the **Shanghai Stock Exchange website (www.sse.com.cn)**, and the custody location is the company's **Board Secretary's Office**[15](index=15&type=chunk) [IV. Overview of Company Shares/Depositary Receipts](index=6&type=section&id=IV.%20Overview%20of%20Company%20Shares%2FDepositary%20Receipts) This section overviews the company's A-shares, listed on the STAR Market under stock code **688163** - The company's shares are **RMB ordinary shares (A-shares)**, listed on the **STAR Market of the Shanghai Stock Exchange**[16](index=16&type=chunk) - The stock abbreviation is **"Salubris Bio"**, and the stock code is **"688163"**[16](index=16&type=chunk) [VI. Company's Key Accounting Data and Financial Indicators](index=7&type=section&id=VI.%20Company%27s%20Key%20Accounting%20Data%20and%20Financial%20Indicators) H1 2025 revenue grew **2.82%** to **100.82 million yuan**, with net profit up **2.07%** and non-recurring net profit up **25.08%** Key Accounting Data for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 100,819,362.78 yuan | 98,058,273.88 yuan | 2.82 | | Total Profit | 37,765,257.67 yuan | 37,054,710.36 yuan | 1.92 | | Net Profit Attributable to Shareholders of Listed Company | 32,976,733.37 yuan | 32,307,812.26 yuan | 2.07 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 28,527,072.70 yuan | 22,807,500.95 yuan | 25.08 | | Net Cash Flow from Operating Activities | -21,235,024.04 yuan | -3,045,200.43 yuan | N/A | Key Financial Indicators for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (yuan/share) | 0.30 | 0.30 | 0.00 | | Diluted Earnings Per Share (yuan/share) | 0.30 | 0.30 | 0.00 | | Basic EPS Excluding Non-Recurring Items (yuan/share) | 0.26 | 0.21 | 23.81 | | Weighted Average Return on Net Assets (%) | 2.98 | 2.93 | Increased by 0.05 percentage points | | Weighted Average Return on Net Assets Excluding Non-Recurring Items (%) | 2.57 | 2.07 | Increased by 0.50 percentage points | | R&D Investment as % of Operating Revenue (%) | 8.41 | 12.64 | Decreased by 4.23 percentage points | - Operating revenue growth was primarily driven by increased sales of **antivenom series products**[19](index=19&type=chunk) - Net cash flow from operating activities decreased by **18.19 million yuan**, mainly due to slower collection of accounts receivable[20](index=20&type=chunk) - R&D investment as a percentage of operating revenue decreased by **4.23 percentage points**, primarily because of a year-on-year reduction in technical service fees for clinical and pre-clinical safety evaluation studies of certain projects in the prior period[20](index=20&type=chunk) [VIII. Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=VIII.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) This section details H1 2025 non-recurring gains and losses, totaling **4.45 million yuan**, from financial asset fair value changes, government grants, and asset disposals Non-Recurring Gains and Losses Items and Amounts for H1 2025 | Non-Recurring Gains and Losses Item | Amount (yuan) | | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 32,980.71 | | Government Grants Recognized in Current Profit/Loss | 333,786.50 | | Fair Value Changes and Disposal Gains/Losses from Financial Assets and Liabilities Held by Non-Financial Enterprises | 5,036,477.06 | | Other Non-Operating Income and Expenses | -165,618.46 | | Less: Income Tax Impact | 787,965.14 | | Total | 4,449,660.67 | [Part III Management Discussion and Analysis](index=9&type=section&id=Part%20III%20Management%20Discussion%20and%20Analysis) [I. Company's Industry and Main Business During the Reporting Period](index=9&type=section&id=I.%20Company%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company, a leader in antiserum and antitoxin manufacturing, offers exclusive antivenom products and is expanding its R&D pipeline - The company operates in the **biopharmaceutical manufacturing sector**, specifically in **antiserum and antitoxin production**[24](index=24&type=chunk) - The company's main products include **anti-Agkistrodon antivenom, anti-Deinagkistrodon antivenom, anti-Naja antivenom, anti-Bungarus antivenom, equine tetanus immunoglobulin (F(ab')2), and anti-rabies serum**[28](index=28&type=chunk) - The **antivenom series products** are exclusively produced and sold domestically, serving as the sole specific treatment for snakebites[29](index=29&type=chunk) - The company initiated two new R&D projects: **broad-spectrum antivenom antibody** and **recombinant snake venom hemagglutinase**, both currently in the laboratory research phase[41](index=41&type=chunk)[42](index=42&type=chunk) - The **anti-viper antivenom R&D project** is in Phase II clinical research, while the **anti-bee venom serum R&D project** is in the Pre-IND stage[38](index=38&type=chunk)[39](index=39&type=chunk) - The **rapid snake venom detection diagnostic reagent R&D project (Naja venom)** is in clinical research, and the **Agkistrodon and Deinagkistrodon venom rapid detection diagnostic reagents** are in pre-clinical trial research[40](index=40&type=chunk) [II. Discussion and Analysis of Operations](index=13&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) Operating performance showed steady growth with slight increases in revenue and net profit, while R&D investment decreased **31.63%** H1 2025 Operating Performance Overview | Indicator | Current Period (million yuan) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 100.82 | 2.82 | | Net Profit Attributable to Shareholders of Listed Company | 32.98 | 2.07 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 28.53 | 25.08 | - R&D expenses decreased by **31.63%** year-on-year, primarily due to varying investment levels in R&D projects across different periods, which is considered normal fluctuation[45](index=45&type=chunk) - The company initiated two new projects, **broad-spectrum antivenom antibody** and **recombinant snake venom hemagglutinase**, currently in laboratory research, aiming to provide more universal, safe, and convenient specific treatments for snakebites and higher-quality hemostatic drugs[48](index=48&type=chunk) - The company continues to advance the online listing of **anti-rabies serum** on drug procurement information platforms in various provinces, with successful listings in some provinces[50](index=50&type=chunk) [III. Analysis of Core Competitiveness During the Reporting Period](index=15&type=section&id=III.%20Analysis%20of%20Core%20Competitiveness%20During%20the%20Reporting%20Period) Core competitiveness stems from exclusive products, pioneering technologies, robust R&D, and a nationwide market presence, despite a **31.63%** decrease in R&D investment - The company's **antivenom series products** are domestically exclusive emergency medicines, and **equine tetanus immunoglobulin** is an upgraded product of tetanus antitoxin (TAT), with significantly fewer side effects than TAT[51](index=51&type=chunk) - The company possesses core proprietary and patented technologies in antiserum and antitoxin R&D and production, including **toxin proteomics research, antigen purification, immunization and plasmapheresis, adjuvant development, efficient virus inactivation, pepsin digestion process optimization, column chromatography purification, and antitoxin protective efficacy testing**[52](index=52&type=chunk)[56](index=56&type=chunk)[57](index=57&type=chunk)[58](index=58&type=chunk)[59](index=59&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk)[63](index=63&type=chunk)[64](index=64&type=chunk) - During the reporting period, the company filed **1 new invention patent application**, accumulating **19 invention patents** and **1 software copyright**[67](index=67&type=chunk) R&D Investment Overview | Indicator | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Expensed R&D Investment | 8,476,409.41 | 12,398,153.48 | -31.63 | | Total R&D Investment | 8,476,409.41 | 12,398,153.48 | -31.63 | | Total R&D Investment as % of Operating Revenue (%) | 8.41 | 12.64 | Decreased by 4.23 percentage points | - Total R&D investment decreased by **31.63%** year-on-year, mainly due to a reduction in outsourced technical service fees for projects like anti-viper antivenom clinical research and anti-bee venom serum pre-clinical safety evaluation, which had higher investments in the prior period[70](index=70&type=chunk) Key R&D Projects Overview | No | Project Name | Estimated Total Investment (million yuan) | Current Period Investment (million yuan) | Accumulated Investment (million yuan) | Progress or Stage Achievements | Target Objective | Technological Level | Specific Application Prospects | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 1 | Anti-Viper Antivenom Registration and Clinical Trial Research | 25.70 | 0.14 | 17.17 | Phase II clinical research | Obtain New Drug Certificate | Domestically Leading | Viper Bites | | 2 | Anti-Rabies Serum New Process Research | 17.55 | 1.17 | 15.45 | Product continuous improvement | Develop Higher Quality Drugs | Domestically Leading | Rabies Prevention | | 3 | Equine Tetanus Immunoglobulin (F(ab')2) New Process Research | 40.00 | 0.17 | 39.01 | Product continuous improvement | Develop Higher Quality Drugs | Domestically Leading | Tetanus Prevention and Treatment | | 4 | R&D of Anti-Bee Venom Serum | 35.00 | 3.37 | 29.51 | Pre-clinical research | Obtain New Drug Certificate | Domestically Leading | Bee Stings | | 5 | R&D of Rapid Snake Venom Detection Diagnostic Reagents | 25.00 | 2.30 | 18.14 | Naja venom rapid detection diagnostic reagent in clinical research; Agkistrodon and Deinagkistrodon venom rapid detection diagnostic reagents in pre-clinical trial stage | Obtain Medical Device Registration Certificate | Domestically Leading | Detection and Diagnosis of Snakebite Types | | 6 | R&D of Broad-Spectrum Antivenom Antibody | 244.00 | 0.65 | 0.65 | Laboratory research stage | Obtain New Drug Certificate | Internationally Leading | Venomous Snakebites | | 7 | R&D of Recombinant Snake Venom Hemagglutinase | 185.90 | 0.68 | 0.68 | Laboratory research stage | Obtain New Drug Certificate | Domestically Leading | Hemostasis | R&D Personnel Overview | Indicator | Current Period | Prior Period | | :--- | :--- | :--- | | Number of Company R&D Personnel (persons) | 36 | 41 | | R&D Personnel as % of Total Company Staff (%) | 11.11 | 12.73 | | Total R&D Personnel Compensation (million yuan) | 4.39 | 5.58 | | Average R&D Personnel Compensation (million yuan) | 0.12 | 0.14 | [IV. Risk Factors](index=19&type=section&id=IV.%20Risk%20Factors) The company faces risks including core technology leakage, product safety, market competition, supply chain issues, product concentration, and tax policy changes - Core Competitiveness Risk: **Leakage of core technology or experimental data by personnel** could diminish product market position[76](index=76&type=chunk)[77](index=77&type=chunk) - Product Safety Risk: Products manufactured using equine immunity carry the risk of **known or unknown pathogens not being completely inactivated**[78](index=78&type=chunk) - Market Risk: **Product price controls or intensified competition** could lead to price reductions or market share loss, particularly if the exclusive status of antivenom is compromised[79](index=79&type=chunk)[80](index=80&type=chunk) - Operational Risk: **Shortage of biological immune host horses or immunization failures** could disrupt normal production and R&D[81](index=81&type=chunk)[86](index=86&type=chunk) - Financial Risk: **Relatively undiversified product structure, inventory impairment provisions, changes in tax preferential policies, and capital-raising projects** could lead to a decline in return on net assets[82](index=82&type=chunk)[87](index=87&type=chunk)[88](index=88&type=chunk)[89](index=89&type=chunk) [V. Key Operating Performance During the Reporting Period](index=22&type=section&id=V.%20Key%20Operating%20Performance%20During%20the%20Reporting%20Period) H1 2025 revenue grew **2.82%** to **100.82 million yuan**, net profit increased **2.07%**, total assets rose **1.38%**, and accounts receivable increased **168.77%** H1 2025 Key Operating Data | Indicator | Amount (million yuan) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 100.82 | 2.82 | | Net Profit Attributable to Shareholders of Listed Company | 32.98 | 2.07 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 28.53 | 25.08 | H1 2025 Asset and Liability Status | Indicator | Period-End Balance (million yuan) | Change from Beginning of Period (%) | | :--- | :--- | :--- | | Total Assets | 1,135.53 | 1.38 | | Net Assets Attributable to Shareholders of Listed Company | 1,106.83 | 1.03 | - Operating revenue increased by **2.82%**, primarily due to increased sales of **antivenom series products**[92](index=92&type=chunk) - Net cash flow from operating activities decreased, mainly due to **slower collection of accounts receivable**[92](index=92&type=chunk) - R&D expenses decreased by **31.63%**, primarily due to a reduction in outsourced technical service fees compared to the prior period's higher investment[92](index=92&type=chunk) Changes in Key Financial Statement Items | Item | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 100,819,362.78 | 98,058,273.88 | 2.82 | | Operating Cost | 22,843,412.63 | 22,982,176.35 | -0.60 | | Selling Expenses | 21,958,773.94 | 22,278,261.72 | -1.43 | | Administrative Expenses | 11,127,520.58 | 10,494,656.68 | 6.03 | | Financial Expenses | -1,069,707.65 | -919,048.80 | N/A | | R&D Expenses | 8,476,409.41 | 12,398,153.48 | -31.63 | | Net Cash Flow from Operating Activities | -21,235,024.04 | -3,045,200.43 | N/A | | Net Cash Flow from Investing Activities | -6,015,110.75 | 46,082,473.82 | -113.05 | | Net Cash Flow from Financing Activities | -21,642,000.00 | -21,642,000.00 | N/A | [(III) Analysis of Assets and Liabilities](index=23&type=section&id=(III)%20Analysis%20of%20Assets%20and%20Liabilities) Period-end asset and liability changes include a **168.77%** rise in accounts receivable, increased construction in progress, and a **610.07%** surge in taxes payable Changes in Key Assets and Liabilities | Item Name | Current Period-End Balance (yuan) | Current Period-End Balance as % of Total Assets (%) | Prior Year-End Balance (yuan) | Prior Year-End Balance as % of Total Assets (%) | Change from Prior Year-End (%) | Explanation | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Accounts Receivable | 98,582,846.11 | 8.68 | 36,678,957.69 | 3.27 | 168.77 | High sales in Q2; slower collection from some customers | | Prepayments | 128,500.00 | 0.01 | 488,112.00 | 0.04 | -73.67 | Decrease in prepayments to suppliers for daily operations | | Other Current Assets | 20,597,899.56 | 1.81 | 11,811,112.16 | 1.05 | 74.39 | Increase in time deposit balance | | Construction in Progress | 63,653,512.88 | 5.61 | 41,840,485.62 | 3.74 | 52.13 | Continued progress in factory expansion for capital-raising projects | | Other Non-Current Assets | 21,094,954.85 | 1.86 | 14,662,409.70 | 1.31 | 43.87 | Prepayment for equipment for capital-raising project factory expansion | | Accounts Payable | 1,888,452.95 | 0.17 | 1,311,620.50 | 0.12 | 43.98 | Increase in unpaid purchase amounts | | Contract Liabilities | 3,729,443.79 | 0.33 | 2,204,866.20 | 0.20 | 69.15 | Increase in sales discounts accrued for sales contracts | | Employee Compensation Payable | 4,873,189.22 | 0.43 | 8,138,301.13 | 0.73 | -40.12 | Year-end bonuses accrued at prior year-end were paid during the reporting period | | Taxes Payable | 7,911,037.06 | 0.70 | 1,114,122.04 | 0.10 | 610.07 | Corporate income tax, VAT, and individual income tax not yet paid | | Other Current Liabilities | 155,744.64 | 0.01 | 66,146.00 | 0.01 | 135.46 | Increase in deferred output VAT corresponding to contract liabilities | [(IV) Analysis of Investment Status](index=25&type=section&id=(IV)%20Analysis%20of%20Investment%20Status) Period-end trading financial assets totaled **611.87 million yuan**, with fair value change gains of **0.66 million yuan** from purchases and sales Changes in Trading Financial Assets | Asset Category | Beginning Balance (yuan) | Fair Value Change Gains/Losses for Current Period (yuan) | Current Period Purchases (yuan) | Current Period Sales/Redemptions (yuan) | Ending Balance (yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets | 641,207,523.29 | 661,079.45 | 858,000,000.00 | 888,000,000.00 | 611,868,602.74 | [(VI) Analysis of Major Holding and Participating Companies](index=26&type=section&id=(VI)%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The main subsidiary, Shanghai Salubris Bio-tech Dafeng Co., Ltd., focuses on animal immune plasma, with **50 million yuan** registered capital and **0.86 million yuan** net profit Key Subsidiary Financial Data | Company Name | Company Type | Main Business | Registered Capital (yuan) | Total Assets (yuan) | Net Assets (yuan) | Operating Revenue (yuan) | Operating Profit (yuan) | Net Profit (yuan) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shanghai Salubris Bio-tech Dafeng Co., Ltd. | Subsidiary | Collection and Sale of Animal Immune Plasma | 50,000,000.00 | 125,413,345.19 | 51,326,168.33 | 16,069,540.09 | 1,175,751.41 | 857,999.78 | [Part IV Corporate Governance, Environment, and Society](index=27&type=section&id=Part%20IV%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) [I. Changes in Company Directors, Senior Management, and Core Technical Personnel](index=27&type=section&id=I.%20Changes%20in%20Company%20Directors%2C%20Senior%20Management%2C%20and%20Core%20Technical%20Personnel) The company's Chief Financial Officer changed, with **Mr. Li Shaoyang** resigning and **Mr. Liu Jinbao** appointed as the new CFO Changes in Directors and Senior Management | Name | Position Held | Change | | :--- | :--- | :--- | | Li Shaoyang | Former Chief Financial Officer | Resigned | | Liu Jinbao | Chief Financial Officer | Appointed | - Mr. **Liu Jinbao** was appointed as the company's Chief Financial Officer on **February 7, 2025**, following approval by the fourth Board of Directors' fourth meeting[101](index=101&type=chunk) [II. Profit Distribution or Capital Reserve Conversion Plan](index=27&type=section&id=II.%20Profit%20Distribution%20or%20Capital%20Reserve%20Conversion%20Plan) The Board approved a H1 2025 cash dividend of **1.20 yuan per 10 shares**, totaling **12.99 million yuan** H1 2025 Profit Distribution Plan | Indicator | Amount | | :--- | :--- | | Distribution or Conversion | Yes | | Bonus Shares per 10 Shares (shares) | 0 | | Dividend per 10 Shares (yuan) (tax inclusive) | 1.20 | | Capitalization per 10 Shares (shares) | 0 | - The total proposed cash dividend is **12,986,400.00 yuan (tax inclusive)**, representing **39.38%** of the net profit attributable to shareholders of the listed company in the consolidated financial statements for January-June 2025[101](index=101&type=chunk) - This profit distribution plan was approved by the **eighth meeting of the fourth Board of Directors** and does not require shareholder approval[102](index=102&type=chunk) [IV. Environmental Information of Listed Companies and Their Major Subsidiaries Required to Disclose Environmental Information by Law](index=28&type=section&id=IV.%20Environmental%20Information%20of%20Listed%20Companies%20and%20Their%20Major%20Subsidiaries%20Required%20to%20Disclose%20Environmental%20Information%20by%20Law) The company is on the list of enterprises legally required to disclose environmental information List of Enterprises Required to Disclose Environmental Information by Law | No | Enterprise Name | Query Index for Legally Disclosed Environmental Information Report | | :--- | :--- | :--- | | 1 | Shanghai Salubris Bio-tech Co., Ltd. | Enterprise Environmental Information Disclosure System (Shanghai) https://e2.sthj.sh.gov.cn/jsp/view/hjpl/index.jsp | [Part V Significant Matters](index=29&type=section&id=Part%20V%20Significant%20Matters) [I. Fulfillment of Commitments](index=29&type=section&id=I.%20Fulfillment%20of%20Commitments) Controlling shareholders, management, and core technical personnel have strictly fulfilled IPO-related share lock-up commitments and other long-term pledges - Controlling shareholders, actual controllers, shareholders holding **5% or more**, shareholding platforms, core technical personnel, senior management, and supervisors have all strictly fulfilled their **share lock-up commitments**[106](index=106&type=chunk)[109](index=109&type=chunk)[111](index=111&type=chunk)[112](index=112&type=chunk)[113](index=113&type=chunk)[116](index=116&type=chunk)[118](index=118&type=chunk) - The company, its controlling shareholders, actual controllers, all directors (excluding independent directors), and all senior management have committed to implementing the **stock price stabilization plan**[123](index=123&type=chunk) - The company, its actual controllers, directors, and senior management have committed to measures to **enhance immediate returns**, including strengthening main business, managing raised funds, accelerating project progress, improving management incentives, and implementing a proactive profit distribution policy[130](index=130&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk)[133](index=133&type=chunk)[134](index=134&type=chunk) - The company, its actual controllers, all directors, supervisors, and senior management commit to **compensating investors for losses** if the prospectus contains false records, misleading statements, or major omissions[144](index=144&type=chunk) - Controlling shareholders and actual controllers commit to **avoiding horizontal competition** by not engaging in any business or activities that constitute or may constitute horizontal competition with the company and its controlled subsidiaries[158](index=158&type=chunk) [XII. Explanation of Progress in Use of Raised Funds](index=55&type=section&id=XII.%20Explanation%20of%20Progress%20in%20Use%20of%20Raised%20Funds) IPO net proceeds were **784.92 million yuan**, with **283.69 million yuan** invested (**36.14%** progress); **550 million yuan** in idle funds are used for cash management Overall Use of Raised Funds | Indicator | Amount (yuan) | | :--- | :--- | | Net Proceeds from Raised Funds | 784,923,575.78 | | Total Investment Pledged in Prospectus | 400,000,000.00 | | Total Over-Raised Funds | 384,923,575.78 | | Cumulative Raised Funds Invested as of Period-End | 283,688,338.64 | | Cumulative Investment Progress of Raised Funds as of Period-End (%) | 36.14 | | Amount Invested This Year | 47,696,703.06 | Detailed Use of Raised Funds for Investment Projects | No | Project Name | Planned Total Investment of Raised Funds (yuan) | Cumulative Raised Funds Invested as of Period-End (yuan) | Cumulative Investment Progress as of Period-End (%) | | :--- | :--- | :--- | :--- | :--- | | 1 | Specialty New Drug and Innovative Technology R&D Project | 200,000,000.00 | 48,308,510.28 | 24.15 | | 2 | Emergency (Rescue) Drug Emergency Network Service Project | 50,000,000.00 | 44,065,560.10 | 88.13 | | 3 | Shanghai Salubris Bio-tech Co., Ltd. Factory Expansion Project | 150,000,000.00 | 68,462,281.15 | 45.64 | | 4 | Project Surplus Funds Supplementing Working Capital | 7,851,987.11 | 7,851,987.11 | N/A | | 5 | Permanent Supplement to Working Capital | 115,000,000.00 | 115,000,000.00 | 100.00 | - The **"Emergency (Rescue) Drug Emergency Network Service Project"** has been completed, with **7,851,987.11 yuan** of surplus raised funds used to supplement working capital[165](index=165&type=chunk) - The company utilizes idle raised funds, not exceeding **550 million yuan**, for cash management, with a term of up to **12 months** and revolving use[170](index=170&type=chunk) [Part VI Share Changes and Shareholder Information](index=58&type=section&id=Part%20VI%20Share%20Changes%20and%20Shareholder%20Information) [I. Changes in Share Capital](index=58&type=section&id=I.%20Changes%20in%20Share%20Capital) During the reporting period, the company's total ordinary shares and share capital structure remained unchanged - During the reporting period, there were **no changes** in the company's total ordinary shares or share capital structure[173](index=173&type=chunk) [II. Shareholder Information](index=58&type=section&id=II.%20Shareholder%20Information) As of period-end, the company had **7,724** ordinary shareholders; the top three held **34.05%**, **22.18%**, and **2.77%** respectively, all with restricted shares Total Ordinary Shareholders as of Period-End | Indicator | Number (accounts) | | :--- | :--- | | Total Ordinary Shareholders | 7,724 | Top Ten Shareholders' Shareholding Status | Shareholder Name | Period-End Shareholding (shares) | Percentage (%) | Number of Restricted Shares Held (shares) | Shareholder Nature | | :--- | :--- | :--- | :--- | :--- | | Zhao Aixian | 36,848,000 | 34.05 | 36,848,000 | Domestic Natural Person | | Shanghai Zhiyuan Investment Co., Ltd. | 24,000,000 | 22.18 | 24,000,000 | Domestic Non-State-Owned Legal Person | | Shanghai Saipai Investment Partnership (Limited Partnership) | 3,000,000 | 2.77 | 3,000,000 | Domestic Non-State-Owned Legal Person | | Xie Li | 1,950,000 | 1.80 | 0 | Domestic Natural Person | | Wang Yuejin | 1,269,000 | 1.17 | 0 | Domestic Natural Person | | Zhang Lei | 1,189,000 | 1.10 | 0 | Domestic Natural Person | | Yu Yuming | 670,200 | 0.62 | 0 | Domestic Natural Person | | Yang Haizhen | 626,760 | 0.58 | 0 | Domestic Natural Person | | Li Huichi | 621,884 | 0.57 | 0 | Domestic Natural Person | | Zhang Decheng | 553,500 | 0.51 | 0 | Domestic Natural Person | - **Zhao Aixian, Fan Zhihe, and Fan Tiejiong** are parties acting in concert; **Zhiyuan Investment** was established by Fan Zhihe and Fan Tiejiong, and **Saipai Investment** is the company's employee shareholding platform[177](index=177&type=chunk)[178](index=178&type=chunk) Top Ten Restricted Shareholders' Shareholding and Restriction Conditions | No | Restricted Shareholder Name | Number of Restricted Shares Held (shares) | Date Available for Listing and Trading | Restriction Condition | | :--- | :--- | :--- | :--- | :--- | | 1 | Zhao Aixian | 36,848,000 | 2025年9月11日 | IPO Lock-up | | 2 | Shanghai Zhiyuan Investment Co., Ltd. | 24,000,000 | 2025年9月11日 | IPO Lock-up | | 3 | Shanghai Saipai Investment Partnership (Limited Partnership) | 3,000,000 | 2025年9月11日 | IPO Lock-up | [Part VII Bond-Related Information](index=62&type=section&id=Part%20VII%20Bond-Related%20Information) [I. Corporate Bonds (Including Enterprise Bonds) and Non-Financial Enterprise Debt Financing Instruments](index=62&type=section&id=I.%20Corporate%20Bonds%20(Including%20Enterprise%20Bonds)%20and%20Non-Financial%20Enterprise%20Debt%20Financing%20Instruments) During the reporting period, the company had no corporate bonds or non-financial enterprise debt financing instruments [II. Convertible Corporate Bonds](index=62&type=section&id=II.%20Convertible%20Corporate%20Bonds) During the reporting period, the company had no convertible corporate bonds [Part VIII Financial Report](index=63&type=section&id=Part%20VIII%20Financial%20Report) [I. Audit Report](index=63&type=section&id=I.%20Audit%20Report) This semi-annual report is unaudited - This semi-annual report is **unaudited**[4](index=4&type=chunk) [II. Financial Statements](index=63&type=section&id=II.%20Financial%20Statements) This section presents the company's H1 2025 consolidated and parent company financial statements, including balance sheets, income statements, and cash flow statements - Financial statements include the **Consolidated Balance Sheet, Parent Company Balance Sheet, Consolidated Income Statement, Parent Company Income Statement, Consolidated Cash Flow Statement, Parent Company Cash Flow Statement, Consolidated Statement of Changes in Owners' Equity, and Parent Company Statement of Changes in Owners' Equity**[184](index=184&type=chunk)[189](index=189&type=chunk)[193](index=193&type=chunk)[197](index=197&type=chunk)[200](index=200&type=chunk)[204](index=204&type=chunk)[206](index=206&type=chunk)[210](index=210&type=chunk) [III. Company Basic Information](index=81&type=section&id=III.%20Company%20Basic%20Information) Shanghai Salubris Bio-tech Co., Ltd., established in **1999** and listed in **2022**, specializes in antiserum and antitoxin biopharmaceuticals - The company was established on **November 9, 1999**, and listed on the **Shanghai Stock Exchange on March 11, 2022**[215](index=215&type=chunk) - As of **June 30, 2025**, the company's total share capital was **108.22 million shares**, and its registered capital was **108.22 million yuan**[216](index=216&type=chunk) - The company's main business is the R&D, production, and sales of **antiserum and antitoxin biopharmaceuticals**, with key products including various **antivenoms, equine tetanus immunoglobulin (F(ab')2), and anti-rabies serum**[217](index=217&type=chunk) [IV. Basis of Financial Statement Preparation](index=81&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) These financial statements are prepared on a going concern basis, adhering to enterprise accounting standards and key accounting policies - Financial statements are prepared on a **going concern basis**, in accordance with **enterprise accounting standards** and significant accounting policies and estimates[218](index=218&type=chunk) - The company has the ability to **continue as a going concern for the next 12 months** from the end of this reporting period, with no significant matters affecting its going concern ability[219](index=219&type=chunk) [V. Significant Accounting Policies and Estimates](index=81&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's specific accounting policies and estimates across various areas, ensuring financial report accuracy - The company prepares its financial statements in accordance with **Enterprise Accounting Standards** and their application guidelines, interpretations, and other relevant regulations[221](index=221&type=chunk) - Revenue is recognized when customers obtain control of the related goods, with major products like **antivenom series and equine tetanus immunoglobulin** recognized under this principle[342](index=342&type=chunk)[349](index=349&type=chunk) - Inventories are measured at the **lower of cost and net realizable value**, with different impairment provision methods for various inventory categories (raw materials, self-made semi-finished goods, work-in-progress, finished goods, consumable biological assets), specifically for **equine tetanus immunoglobulin plasma**, where net realizable value is estimated based on aging combinations[280](index=280&type=chunk)[281](index=281&type=chunk)[282](index=282&type=chunk) - R&D expenditures are divided into **research and development phases**; research phase expenditures are expensed, while development phase expenditures are recognized as intangible assets when specific conditions are met, typically after obtaining clinical approval and entering Phase III clinical trials or completing pilot production with products meeting expected quality standards[315](index=315&type=chunk)[317](index=317&type=chunk) [VI. Taxation](index=110&type=section&id=VI.%20Taxation) This section details the company's main tax categories and rates, including VAT (3% for biological products) and a **15%** preferential corporate income tax rate Main Tax Categories and Rates | Tax Category | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Sale of Goods or Provision of Taxable Services | 3%、6% | | Property Tax | Calculated at 1.2% of the remaining value after a one-time 30% deduction from the original property value | 1.2% | | Urban Maintenance and Construction Tax | Amount of Turnover Tax Payable | 5%、7% | | Education Surcharge | Amount of Turnover Tax Payable | 3% | | Local Education Surcharge | Amount of Turnover Tax Payable | 2% | | Corporate Income Tax | Taxable Income | 15%、25% | - The company and its subsidiary, Salubris Dafeng, both apply a **simplified method to pay VAT at a 3% levy rate** when selling biological products[372](index=372&type=chunk) - As a **high-tech enterprise**, the company enjoys a **15% preferential corporate income tax rate**[374](index=374&type=chunk) [VII. Notes to Consolidated Financial Statement Items](index=111&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes to consolidated financial statement items, including assets, liabilities, equity, and profit/loss Cash and Bank Balances | Item | Period-End Balance (yuan) | Beginning Balance (yuan) | | :--- | :--- | :--- | | Cash on Hand | 26,621.00 | 28,221.00 | | Bank Deposits | 133,314,612.87 | 182,078,916.22 | | Total | 133,341,233.87 | 182,107,137.22 | Trading Financial Assets | Item | Period-End Balance (yuan) | Beginning Balance (yuan) | | :--- | :--- | :--- | | Structured Deposits | 611,868,602.74 | 641,207,523.29 | | Total | 611,868,602.74 | 641,207,523.29 | Aging Analysis of Accounts Receivable | Aging | Period-End Book Balance (yuan) | Beginning Book Balance (yuan) | | :--- | :--- | :--- | | Within 1 year | 102,074,997.27 | 38,593,183.70 | | 1 to 2 years | 1,789,723.25 | 17,148.00 | | 2 to 3 years | 1,413.00 | 0.00 | | Total | 103,866,133.52 | 38,610,331.70 | Inventory Classification and Impairment Provisions | Item | Period-End Book Value (yuan) | Beginning Book Value (yuan) | | :--- | :--- | :--- | | Raw Materials | 4,447,052.87 | 3,823,128.11 | | Work-in-Progress | 12,730,222.39 | 11,222,946.11 | | Finished Goods | 5,268,415.10 | 8,746,585.09 | | Consumable Biological Assets | 103,498.68 | 129,796.10 | | Self-Made Semi-Finished Goods | 19,158,854.02 | 19,353,007.53 | | Goods in Transit | 697,148.10 | 0.00 | | Total | 42,405,191.16 | 43,275,462.94 | Construction in Progress | Item | Period-End Book Value (yuan) | Beginning Book Value (yuan) | | :--- | :--- | :--- | | Phase II Factory Expansion | 59,941,159.99 | 37,891,132.73 | | Buffer Workshop | 3,421,903.09 | 3,421,903.09 | | Other Minor Projects | 290,449.80 | 395,449.80 | | Software | 0.00 | 132,000.00 | | Total | 63,653,512.88 | 41,840,485.62 | Composition of R&D Expenses | Item | Current Period Amount (yuan) | Prior Period Amount (yuan) | | :--- | :--- | :--- | | Employee Compensation | 4,391,102.61 | 4,630,578.03 | | Technical Service Fees | 759,542.40 | 3,364,395.10 | | Material Consumption | 1,407,284.89 | 2,452,898.60 | | Depreciation Expense | 1,796,100.43 | 1,756,855.21 | | Transportation and Travel Expenses | 42,934.79 | 62,671.95 | | Office Expenses | 20,189.28 | 33,137.25 | | Other | 59,255.01 | 97,617.34 | | Total | 8,476,409.41 | 12,398,153.48 | Composition of Financial Expenses | Item | Current Period Amount (yuan) | Prior Period Amount (yuan) | | :--- | :--- | :--- | | Interest Expense | 84,036.12 | 311,586.54 | | Less: Interest Income | 1,037,643.75 | 1,222,685.50 | | Exchange Gains/Losses | -126,231.44 | -20,317.94 | | Bank Charges | 10,131.42 | 12,368.10 | | Total | -1,069,707.65 | -919,048.80 |

2025年半年度每股分配比例：每10股派发现金红利1.20元（含税），不送 红股，不以资本公积金转增股本。 2025年半年度利润分配以实施权益分派股权登记日登记的总股数为基数， 具体日期将在权益分派实施公告中明确。 证券代码：688163 证券简称：赛伦生物 公告编号：2025-020 上海赛伦生物技术股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于提 请股东大会授权董事会进行 2025 年度中期分红的议案》，同意授权董事会在满足 现金分红条件，不影响公司正常经营和持续发展的情况下，在 2025 年中期（半 年度报告或第三季度报告披露期间）适当增加一次分红，制定并实施具体现金分 红方案。 授权事项如下：1、中期分红的前提条件：（1）公司在当期盈利、累计未分 配利润为正；（2）公司现金流可以满足正常经营和持续发展的需求。2、2025 年 中期现金分红上限为：不超过相应 ...

Core Viewpoint - The company has initiated the sales of its rabies immune globulin product, which is now listed on drug procurement platforms in certain provinces, marking a significant step in its market presence [1] Group 1: Product Development and Sales - The rabies immune globulin product is an existing product that had previously not been sold on a large scale due to distribution channel issues and allergic reactions [1] - Continuous process improvement research is being conducted on the product, with production planned for the second half of 2024 and ongoing efforts to list the product on procurement platforms across provinces in 2025 [1] Group 2: Market Position and Regulatory Status - The rabies immune globulin has a specific role in neutralizing the rabies virus and is used for preventive injections in individuals severely bitten by suspected rabid animals [1] - Currently, the company is the only manufacturer and seller of rabies immune globulin in the market [1] - The product is included in the National Essential Medicines List and the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List [1]

证券之星消息，8月20日，赛伦生物（688163）融资买入670.63万元，融资偿还529.86万元，融资净买入 140.77万元，融资余额1.52亿元，近3个交易日已连续净买入累计714.83万元，近20个交易日中有17个交 易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-20 | 140.77万 | 1.52亿 | 13.22% | | 2025-08-19 | 191.39万 | 1.50亿 | 12.84% | | 2025-08-18 | 382.67万 | 1.48亿 | 12.69% | | 2025-08-15 | -60.93万 | 1.44亿 | 12.39% | | 2025-08-14 | 558.12万 | 1.44亿 | 12.91% | 融券方面，当日无融券交易。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-20 | 1.52亿 | 140.77万 | 0.94% ...